THE INQUIRY: If a molecule is genuinely more consequential for women than for men — if the evidence for its longevity effects is sex-differentiated in ways the industry has not, by and large, communicated — does it change how a woman should think about when to engage with it, and in what form?
THE SYNTHESIS
There is a particular kind of overclaim that settles into wellness culture before the science has had a chance to catch up with the enthusiasm. NAD+ is currently living through exactly that moment. Longevity clinics across three continents are administering nicotinamide adenine dinucleotide by intravenous infusion — frequently at considerable expense, frequently to people whose cellular context has never been assessed — on the basis of a compelling mechanistic story and a research literature that is, in practice, thinner on human clinical evidence than the confidence of its advocates would suggest. A retrospective pilot study comparing IV NAD+ against IV nicotinamide riboside found that both protocols were tolerably safe at thirty days. It found their metabolic outcomes to be variable and inconsistent. Which is, when read honestly, the data telling you that the conditions under which these molecules are being delivered matter enormously — and that the field has not yet mapped those conditions with sufficient precision.
This would be merely cautionary if it were not for a finding that changes the conversation significantly for women specifically. Preclinical work published in 2023 by Kane, Chellappa, Schultz, and colleagues — including work from David Sinclair's group at Harvard — found that long-term NMN treatment increased lifespan by 8.5% in female mice and improved markers of metabolic health, while producing no equivalent lifespan extension in male mice. The sex-differentiated efficacy of NAD+ precursors — a finding consistent enough across animal models to be genuinely notable — has not, by and large, entered the popular conversation. It tends to get summarised as: NAD+ declines with age, supplementation may help. The sex-specific signal in the data gets averaged out.
The mechanism that explains it begins in the ovary. The ovary is among the first organs to experience age-related NAD+ decline — aging, by some estimates, approximately two and a half times faster than the rest of the body. An enzyme called CD38, a significant consumer of cellular NAD+, increases in expression in ovarian tissue with age, depleting the very coenzyme that mitochondria require to maintain the quality of developing oocytes and the integrity of ovarian function. What this means, as a systems matter, is that the NAD+ decline most women begin to experience in their forties is not simply the generic trajectory of cellular aging. It is accelerated by, and in part expressed through, the biological changes preceding menopause — a pattern that compounds with the additional finding that oestrogen itself supports the processes maintaining NAD+ production. The loss of oestrogen and the loss of cellular NAD+ are not parallel and independent events. They are, in part, the same event.
Think of NAD+ as something like a coenzyme that participates in a very large conversation — hundreds of metabolic processes, sirtuin activation, DNA repair, circadian regulation, mitochondrial function — rather than a lever one pulls to produce a predictable outcome. An IV infusion adds one voice to that conversation. What the pilot study's inconsistent metabolic results are probably reflecting is not that NAD+ doesn't work, but that the coenzyme's effects depend entirely on the quality of the conversation it is joining. A well-regulated circadian rhythm, adequate sleep, dietary precursors arriving through genuinely nutrient-dense food, and a mitochondrial environment not saturated with chronic inflammatory noise are the conditions under which the NAD+ conversation produces coherent results. Without them, the drip is a voice in a room that hasn't yet learned the score.
The clinical implication for women — and this is the finding worth sitting with — is that the decade in which NAD+ decline accelerates for women is also the decade in which the intervention is, by the evidence to date, most likely to be efficacious. Not post-menopausal, as an afterthought. Not as a crisis response to fatigue and brain fog that have already arrived. In perimenopause, when the biological conditions that drive the decline are active and the window for building the preconditions of a more supported cellular environment is still open.
THE CONSIDERED RESPONSE
The sophisticated read of the current data is neither dismissal nor enthusiasm. It is sequence. Before the infusion, before the supplement stack, before any form of exogenous NAD+ support, a woman who wants to engage with this territory honestly would do well to understand two things: where her cellular energy and metabolic markers currently sit, and whether the basic conditions for effective NAD+ metabolism are in place. A well-anchored circadian rhythm — consistent sleep and wake times, eating windows aligned with daylight, artificial light after dark treated as the metabolic insult it is — supports the endogenous NAD+ recycling cycle that operates beneath any supplementation. Dietary precursors, arriving through foods that contain meaningful concentrations of NR and NMN (broccoli, avocado, edamame, certain fermented preparations), establish a baseline that no infusion can replicate in isolation. And the chronic inflammatory load — from processed food, poor sleep, unmanaged stress — blunts any cellular intervention's effect before it begins.
The intervention is not the point. The conditions for the intervention are the point. That, it turns out, was always the finding worth reading.
LE PROTOCOLE: Turning the Research into Intelligence
The NAD+ research for women organises around three disciplines: the precursor, the circadian, and the measured. We read them as a single architecture, most consequential in the decade around perimenopause.
The Precursor Foundation: Before any intravenous or oral NAD+ supplement is considered, establish the dietary conditions that support the endogenous salvage pathway. Foods that contain meaningful NR and NMN concentrations — broccoli, edamame, avocado, fermented preparations, certain fish — are not replacements for supplementation but prerequisites for it. The body's internal recycling system, when well-supported, is the primary mechanism. Supplementation is the secondary variable.
The Circadian Anchor: NAD+ recycling is deeply coupled to circadian rhythm. Consistent sleep and wake times, a food window that closes with the light, and the deliberate reduction of artificial light after sunset support the oscillation of NAD+ that the sirtuin system requires. This is not a lifestyle suggestion. It is the biological condition under which the conversation NAD+ is participating in produces legible results.
The AION Atelier Baseline: The metabolic markers most reflective of NAD+ territory — insulin sensitivity, inflammatory load, and mitochondrial health indicators — are readable before any supplementation decision is made. The AION Atelier Baseline reads them together, in the context of where a reader sits relative to menopause, which is the context that makes the numbers actionable rather than abstract.
— The Archive Editors AION Atelier
To receive The Archive, twice weekly — subscribe here.
We do not provide medical advice. We provide the intelligence to ask better questions.
THE SOURCE: Frontiers in Aging (2026) — "Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting."
Kane, Chellappa, Schultz et al., Innovation in Aging (2023) — NMN treatment increases median lifespan 8.5% in female but not male mice; note this was published as conference proceedings in the Innovation in Aging supplement, not as a standalone peer-reviewed paper. The sex-differentiated efficacy signal is real and consistent across the preclinical literature; the human evidence remains early.
Huang et al., Immunity and Ageing (2023) — NAD+ metabolism and ovarian aging; the ovary ages approximately 2.5 times faster than the rest of the body; CD38-mediated NAD+ depletion in ovarian tissue is the specific mechanism described.
The Archive — a publication of AION Atelier. Longevity, with intention.